Want to see HK:3681 full AI Analyst Report?
3681 Stock Chart & Stats
HK$1.10
HK$0.02(1.67%)
At close: 4:00 PM EDT
HK$1.10
HK$0.02(1.67%)
Day’s Range― - ―
52-Week RangeHK$0.96 - HK$2.19
Previous CloseN/A
Volume690.90K
Average Volume (3M)644.65K
Market Cap
HK$1.47B
Enterprise ValueHK$1.43B
Total Cash (Recent Filing)HK$226.21M
Total Debt (Recent Filing)HK$266.78M
Price to Earnings (P/E)―
Beta1.00
Next Earnings
Mar 22, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding1,386,638,300
10 Day Avg. Volume296,850
30 Day Avg. Volume644,650
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)2.91
Price to Sales (P/S)0.00
P/FCF Ratio-15.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.21
Revenue Forecast (FY)HK$8.71M
Bulls Say, Bears Say
Bulls Say
Narrower LossesNarrower losses in 2025 indicate some improvement in cost control or operating performance relative to the prior year. Although the company remains far from profitability, reducing the size of losses can extend financial runway and create a better base for future development and commercialization.
Improved LeverageLower debt and higher equity strengthen the balance sheet compared with 2024, reducing the burden created by earlier elevated leverage. This provides greater financial flexibility for a development-stage biotech, although ongoing losses mean balance-sheet improvement must be sustained.
Antibody Platform And Monetization RoutesA focus on antibody therapeutics gives SinoMab a defined technology and development platform spanning discovery, clinical progress, and potential commercialization. Approved products, licensing, partnerships, and royalties provide several possible long-term monetization routes if candidates succeed.
Bears Say
Revenue CollapseRevenue reaching zero shows that the business has not yet established dependable commercial scale. Persistent revenue volatility makes operating performance difficult to fund internally and leaves future growth dependent on successful product development, approvals, and eventual commercialization.
Structural Cash BurnRecurring negative operating and free cash flow means the company consumes cash to maintain its activities rather than funding them through operations. Even with a slower burn in 2025, continued dependence on external financing can constrain development plans and financial resilience.
Persistent UnprofitabilityConsistent operating and net losses indicate that the current business has not converted research and development activity into sustainable earnings. Until profitability improves, management must balance pipeline investment against funding needs, limiting the company’s ability to self-finance expansion.
SinoMab Bioscience Ltd. News
3681 FAQ
What was SinoMab Bioscience Ltd.’s price range in the past 12 months?
SinoMab Bioscience Ltd. lowest stock price was HK$0.96 and its highest was HK$2.19 in the past 12 months.
What is SinoMab Bioscience Ltd.’s market cap?
SinoMab Bioscience Ltd.’s market cap is HK$1.47B.
When is SinoMab Bioscience Ltd.’s upcoming earnings report date?
SinoMab Bioscience Ltd.’s upcoming earnings report date is Mar 22, 2027 which is in 142 days.
How were SinoMab Bioscience Ltd.’s earnings last quarter?
SinoMab Bioscience Ltd. released its earnings results on Aug 31, 2026. The company reported -HK$0.105 earnings per share for the quarter.
Is SinoMab Bioscience Ltd. overvalued?
According to Wall Street analysts SinoMab Bioscience Ltd.’s price is currently Overvalued.
Does SinoMab Bioscience Ltd. pay dividends?
SinoMab Bioscience Ltd. does not currently pay dividends.
What is SinoMab Bioscience Ltd.’s EPS estimate?
SinoMab Bioscience Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SinoMab Bioscience Ltd. have?
SinoMab Bioscience Ltd. has 1,386,638,300 shares outstanding.
What happened to SinoMab Bioscience Ltd.’s price movement after its last earnings report?
SinoMab Bioscience Ltd. reported an EPS of -HK$0.105 in its last earnings report. Following the earnings report the stock price went up 2.326%.
Which hedge fund is a major shareholder of SinoMab Bioscience Ltd.?
Currently, no hedge funds are holding shares in HK:3681
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
SinoMab Bioscience Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-32.66%
12-Months-Change
Fundamentals
Return on Equity
-41.81%
Trailing 12-Months
Asset Growth
0.01%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
SinoMab Bioscience Ltd.
SinoMab BioScience Limited is a biopharmaceutical enterprise that specializes in the comprehensive process of discovering, developing, producing, and marketing therapeutic solutions for various immunological disorders. Their approach predominantly involves monoclonal antibody (mAb)-based biologics. A key asset in their portfolio is SM03, an innovative anti-CD22 monoclonal antibody. This drug is currently in Phase III clinical trials for rheumatoid arthritis (RA), with additional clinical investigations underway for other immune-related conditions such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), and non-Hodgkin's lymphoma (NHL). The company is also progressing with SN1011, a Bruton's tyrosine kinase inhibitor. This compound is in Phase II clinical trials for pemphigus and has commenced Phase I trials for multiple sclerosis, SLE, and neuromyelitis optica spectrum disorder (NMOSD). Furthermore, SinoMab maintains an active preclinical pipeline. This includes SM17, which targets asthma, atopic dermatitis, and idiopathic pulmonary fibrosis; SM06, intended for RA, SLE, NMOSD, and SS; SM09, in development for NHL and RA; and TNF2, focused on a range of autoimmune diseases. Founded in 2001, SinoMab BioScience Limited is based in Pak Shek Kok, Hong Kong, and conducts its business activities across Mainland China, the Cayman Islands, and Hong Kong.
Technical Analysis
Genor Biopharma Holdings Limited
―
Alphamab Oncology
―
Mabpharm Limited
―
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
―
Shanghai Henlius Biotech, Inc. Class H
―